Data science startup based in Houston focus on neuroscience software nabs $3.78M grant

brain game

A Houston-based software startup received a multimillion-dollar grant from the National Institutes of Health for its work within neurophysiology. Getty Images

Armed with a nearly $3.8 million federal grant, a Houston startup aims to boost neuroscience research around the world.

Vathes LLC, a developer of data management software that collaborates with neuroscience research labs in North America and Europe, recently received the $3.78 million grant from the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative at the National Institutes of Health (NIH). That initiative is part of the National Institute of Neurological Disorders and Stroke.

Vathes says the NIH funding will enable the startup to ramp up its DataJoint Pipelines for Neurophysiology project. The project aims to make open-source software for data science and engineering available to researchers who specialize in neurophysiology, a branch of neuroscience that looks at how the nervous system functions. The pipeline project holds the promise of benefiting research in areas like autism, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease).

The project's principal investigator is Dimitri Yatsenko, vice president of research and development at Vathes. Technologically speaking, neuroscientists are playing catch-up with their counterparts in fields like astrophysics, genomics, and bioinformatics, according to Yatsenko.

Neuroscience "is undergoing a fast transformation in terms of moving toward much more data-centric, data-intensive, computation-intensive, and collaborative projects," Yatsenko says. This means that neuroscientists are "now finding themselves having to quickly adapt to an environment," he adds, "where they have to share big data and computations with their collaborators in very dynamic settings and perform them in a very fluid way."

Yatsenko says the NIH-funded project will help smaller research groups tap into the technical expertise of larger research labs.

Vathes' DataJoint Neuro platform and services, which help create so-called DataJoint pipelines, enable neuroscientists to streamline, analyze, and visualize complex data. Among its customers are Princeton University's Neuroscience Institute and Columbia University's Zuckerman Institute. The federally funded project will empower smaller labs to capitalize on existing DataJoint pipelines as ready-to-go turnkey packages, Yatsenko says.

In essence, Vathes' technology acts as a translator. Big research labs collect data in databases that can vary by computer language and platform. Through the Vathes setup, that data can be incorporated by a lab of any size into algorithmic, machine learning, and artificial intelligence mechanisms, regardless of the computer language or platform.

Edgar Walker, CEO of Vathes, says this simplifies the construction and use of databases, giving scientists "more room to focus on the logic of their data pipeline rather than on the physical implementation of it."

Founded in 2016, Vathes is housed at the Texas Medical Center's Innovation Institute. It employs 10 people. The startup previously received a $100,000 grant from the U.S. Defense Advanced Research Projects Agency (DARPA).

Yatsenko says the project backed by the $3.78 million NIH grant will propel the startup's growth, as it "gives us a big window of opportunity" to provide tools and services that support the startup's open-source software.

"As the NIH and other funding agencies are shifting a lot of their focus to collaborative projects that are distributed among multiple institutions," Walker says, "we've established a reputation as the company that can facilitate such research, be efficient, and actually be cost-effective as well, and make the projects very smooth."

"We expect to continue to grow this business at the same exponential rate," he adds. "We'll keep our fingers crossed and see how things go."


CEO Edgar Walker (left) and Dimitri Yatsenko, vice president of research and development, lead Houston-based Vathes. Photos courtesy of Vathes

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

5 must-read innovation headlines: Pharma giant considers Houston hub + more

Trending news

Editor's note: With May coming to a close, it's time to look back at the biggest innovation headlines for the second half of the month. Major moves were made in May, with NuScale Power entering the market, Persona AI inking a deal with Under Armour, and a pharma giant considering Houston for its next manufacturing hub. Here are the most-read InnovationMap stories published May 15-29, 2026:

1. Pharma giant considers Houston for $1 billion manufacturing campus

Another pharmaceutical giant is considering Houston’s Generation Park for a manufacturing hub. According to a recent filing with the Texas Jobs, Energy, Technology and Innovation (JETI) program, Bristol Myers Squibb Co. is considering the northeast Houston management district for a new $1 billion multi-modal pharmaceutical manufacturing campus.

2. Modular nuclear reactor co. NuScale Power moves into Houston market

The nuclear energy renaissance continues in Texas with an announcement by NuScale Power. The Oregon-based provider of proprietary and innovative advanced small modular reactor (SMR) nuclear technology announced in April it would be opening office space in Houston’s CityCentre.

3. Persona AI teams with Under Armour to protect next-gen robots

Houston-based Persona AI has cemented a partnership with sportswear manufacturer Under Armour to provide materials to protect future robots operating in dangerous conditions. Through the partnership, Persona AI and Under Armour will launch a research initiative to explore whether advanced performance textiles can improve the durability and resilience of humanoid robots operating in harsh industrial environments.

4. Houston quantum energy chip startup emerges from stealth with $12M round

Houston-based Casimir has emerged from stealth with a $12 million seed round to commercialize its quantum energy chip. The round was led by Austin-based Scout Ventures. Lavrock Ventures, Cottonwood Technology, Capital Factory, American Deep Tech, and Tim Draper of Draper Associates also participated in the round. The oversubscribed round exceeded the company’s original $8 million target.

5. Global summit spotlights Houston's growing role in brain health, innovation

The Center for Houston’s Future and UTMB are bringing the Texas Brain Economy Summit back to Houston this summer to continue to position the region as a global leader in brain health. The summit, held June 9-10 at the Texas Medical Center's Helix Park, will bring together more than 500 executives, researchers, policymakers and innovators from around the world to discuss the global brain economy.

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”

View All Listings